Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company (HZNP) Stock Competitors & Peer Comparison
See (HZNP) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HZNP | $116.30 | +0.00% | 26.6B | 61.86 | $1.88 | N/A |
| LLY | $684.43 | +0.00% | 663.7B | 45.77 | $15.32 | +0.83% |
| JNJ | $174.72 | +0.00% | 425.4B | 18.93 | $9.33 | +2.84% |
| ABBV | $204.68 | +0.00% | 365.2B | 97.97 | $2.11 | +3.14% |
| AZN | $78.47 | +0.00% | 245.4B | 29.88 | $2.65 | +1.98% |
| NVS | $122.09 | +0.00% | 240.5B | 18.11 | $6.86 | +3.22% |
| NVO | $50.95 | +0.00% | 232.9B | 13.51 | $3.88 | +3.08% |
| MRK | $82.76 | +0.00% | 210.4B | 12.98 | $6.49 | +3.79% |
| AMGN | $290.29 | +0.00% | 159.6B | 24.26 | $12.22 | +3.13% |
| GILD | $119.02 | +0.00% | 146.9B | 15.29 | $7.74 | +2.63% |
Stock Comparison
HZNP vs LLY Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, LLY has a market cap of 663.7B. Regarding current trading prices, HZNP is priced at $116.30, while LLY trades at $684.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas LLY's P/E ratio is 45.77. In terms of profitability, HZNP's ROE is +0.11%, compared to LLY's ROE of +0.88%. Regarding short-term risk, HZNP is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check LLY's competition here
HZNP vs JNJ Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, JNJ has a market cap of 425.4B. Regarding current trading prices, HZNP is priced at $116.30, while JNJ trades at $174.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas JNJ's P/E ratio is 18.93. In terms of profitability, HZNP's ROE is +0.11%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check JNJ's competition here
HZNP vs ABBV Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, ABBV has a market cap of 365.2B. Regarding current trading prices, HZNP is priced at $116.30, while ABBV trades at $204.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas ABBV's P/E ratio is 97.97. In terms of profitability, HZNP's ROE is +0.11%, compared to ABBV's ROE of +0.86%. Regarding short-term risk, HZNP is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check ABBV's competition here
HZNP vs AZN Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AZN has a market cap of 245.4B. Regarding current trading prices, HZNP is priced at $116.30, while AZN trades at $78.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AZN's P/E ratio is 29.88. In terms of profitability, HZNP's ROE is +0.11%, compared to AZN's ROE of +0.20%. Regarding short-term risk, HZNP is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AZN's competition here
HZNP vs NVS Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVS has a market cap of 240.5B. Regarding current trading prices, HZNP is priced at $116.30, while NVS trades at $122.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVS's P/E ratio is 18.11. In terms of profitability, HZNP's ROE is +0.11%, compared to NVS's ROE of +0.23%. Regarding short-term risk, HZNP is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVS's competition here
HZNP vs NVO Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVO has a market cap of 232.9B. Regarding current trading prices, HZNP is priced at $116.30, while NVO trades at $50.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVO's P/E ratio is 13.51. In terms of profitability, HZNP's ROE is +0.11%, compared to NVO's ROE of +0.78%. Regarding short-term risk, HZNP is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVO's competition here
HZNP vs MRK Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MRK has a market cap of 210.4B. Regarding current trading prices, HZNP is priced at $116.30, while MRK trades at $82.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MRK's P/E ratio is 12.98. In terms of profitability, HZNP's ROE is +0.11%, compared to MRK's ROE of +0.36%. Regarding short-term risk, HZNP is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MRK's competition here
HZNP vs AMGN Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AMGN has a market cap of 159.6B. Regarding current trading prices, HZNP is priced at $116.30, while AMGN trades at $290.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AMGN's P/E ratio is 24.26. In terms of profitability, HZNP's ROE is +0.11%, compared to AMGN's ROE of +0.98%. Regarding short-term risk, HZNP is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AMGN's competition here
HZNP vs GILD Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GILD has a market cap of 146.9B. Regarding current trading prices, HZNP is priced at $116.30, while GILD trades at $119.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GILD's P/E ratio is 15.29. In terms of profitability, HZNP's ROE is +0.11%, compared to GILD's ROE of +0.33%. Regarding short-term risk, HZNP is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GILD's competition here
HZNP vs PFE Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, PFE has a market cap of 143B. Regarding current trading prices, HZNP is priced at $116.30, while PFE trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas PFE's P/E ratio is 13.31. In terms of profitability, HZNP's ROE is +0.11%, compared to PFE's ROE of +0.12%. Regarding short-term risk, HZNP is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check PFE's competition here
HZNP vs SNY Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SNY has a market cap of 123.4B. Regarding current trading prices, HZNP is priced at $116.30, while SNY trades at $49.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SNY's P/E ratio is 16.53. In terms of profitability, HZNP's ROE is +0.11%, compared to SNY's ROE of +0.12%. Regarding short-term risk, HZNP is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SNY's competition here
HZNP vs CELG-RI Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CELG-RI has a market cap of 99.8B. Regarding current trading prices, HZNP is priced at $116.30, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to CELG-RI's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CELG-RI's competition here
HZNP vs BMY Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BMY has a market cap of 98.7B. Regarding current trading prices, HZNP is priced at $116.30, while BMY trades at $47.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BMY's P/E ratio is 19.47. In terms of profitability, HZNP's ROE is +0.11%, compared to BMY's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BMY's competition here
HZNP vs GSK Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GSK has a market cap of 80.2B. Regarding current trading prices, HZNP is priced at $116.30, while GSK trades at $39.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GSK's P/E ratio is 17.63. In terms of profitability, HZNP's ROE is +0.11%, compared to GSK's ROE of +0.24%. Regarding short-term risk, HZNP is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GSK's competition here
HZNP vs BIIB Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BIIB has a market cap of 20.3B. Regarding current trading prices, HZNP is priced at $116.30, while BIIB trades at $134.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BIIB's P/E ratio is 13.28. In terms of profitability, HZNP's ROE is +0.11%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, HZNP is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BIIB's competition here
HZNP vs GRFS Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GRFS has a market cap of 9.1B. Regarding current trading prices, HZNP is priced at $116.30, while GRFS trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GRFS's P/E ratio is 21.02. In terms of profitability, HZNP's ROE is +0.11%, compared to GRFS's ROE of +0.05%. Regarding short-term risk, HZNP is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GRFS's competition here
HZNP vs OGN Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, HZNP is priced at $116.30, while OGN trades at $9.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas OGN's P/E ratio is 3.51. In terms of profitability, HZNP's ROE is +0.11%, compared to OGN's ROE of +0.99%. Regarding short-term risk, HZNP is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check OGN's competition here
HZNP vs CTOR Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CTOR has a market cap of 132.4M. Regarding current trading prices, HZNP is priced at $116.30, while CTOR trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CTOR's P/E ratio is -4.33. In terms of profitability, HZNP's ROE is +0.11%, compared to CTOR's ROE of -0.68%. Regarding short-term risk, HZNP is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CTOR's competition here
HZNP vs SCLX Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLX has a market cap of 125.8M. Regarding current trading prices, HZNP is priced at $116.30, while SCLX trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLX's P/E ratio is -1.16. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLX's ROE of +0.57%. Regarding short-term risk, HZNP is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLX's competition here
HZNP vs SCLXW Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLXW has a market cap of 120.8M. Regarding current trading prices, HZNP is priced at $116.30, while SCLXW trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLXW's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLXW's ROE of +0.57%. Regarding short-term risk, HZNP is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLXW's competition here
HZNP vs MIRA Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MIRA has a market cap of 28.6M. Regarding current trading prices, HZNP is priced at $116.30, while MIRA trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MIRA's P/E ratio is -3.19. In terms of profitability, HZNP's ROE is +0.11%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, HZNP is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MIRA's competition here
HZNP vs SRXH Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SRXH has a market cap of 15.9M. Regarding current trading prices, HZNP is priced at $116.30, while SRXH trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SRXH's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, HZNP is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SRXH's competition here
HZNP vs CRXT Comparison August 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CRXT's P/E ratio is -0.02. In terms of profitability, HZNP's ROE is +0.11%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, HZNP is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CRXT's competition here